Weekly patient-reported symptom monitoring was associated with longer survival across all stages of lung cancer

Design

Post hoc analysis of a multicentre stepped-wedge cluster randomised trial

Population

446 patients with stage I to IV lung cancer at 14 Dutch hospitals

Primary outcome

Overall survival (post hoc)

Effect

Median 26 vs 21 months; adjusted HR 0.80 (95% CI 0.63 to 1.00), p=0.049

SYMPRO-Lung was a stepped-wedge cluster randomised trial at 14 Dutch hospitals. Patients with stage I to IV lung cancer starting new treatment completed weekly online symptom questionnaires for a year once their hospital crossed over to the intervention; earlier patients received standard care. The primary outcome, quality of life, was reported previously. This post hoc analysis, published on 11 September 2026, linked 446 patients to the national cancer registry for survival.

At a median 50 months, median overall survival was 26 months with symptom monitoring and 21 months without (adjusted HR 0.80, 95% CI 0.63 to 1.00, p=0.049). Progression-free survival did not differ significantly (HR 0.86).

Earlier trials linking symptom monitoring to survival were mostly in advanced disease and resource-intensive settings. This extends the signal to all stages and to routine care, though the analysis was post hoc, the upper confidence limit touches 1, and 13% of enrolled patients were excluded.

Web or app-based symptom reporting is increasingly feasible in Indian oncology practice; the essential element is that alerts reach a clinician who acts on them.

• Consider routine weekly patient-reported symptom monitoring for patients on lung cancer treatment
• Make sure reports that cross alert thresholds reach a nurse or doctor who acts the same day
• Use simple digital or phone-based tools that patients can complete at home
• Include patients at all stages, not just those with advanced disease

Why it matters

A low-cost change in how symptoms are reported, not a new drug, was linked to longer survival.

Don't overread it

This was a post hoc survival analysis with a borderline result, not the trial's primary outcome.

The statistics, in plain English

An HR of 0.80 means about 20% lower risk of death, but the confidence interval reaches 1.00 and the p value is just under 0.05, so the result is borderline. Being post hoc, it is supportive rather than definitive.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.